Analysis-Wall Street sees new obesity pills as priced near Wegovy and Zepbound

Eli Lilly and Novo Nordisk are anticipated to price their forthcoming oral GLP-1 weight-loss medications on par with or even slightly below their existing injectable versions, a significant departure from typical new drug pricing strategies. This approach, driven by the oral drugs' comparable efficacy and intense market pressure for affordability, aims to broaden market access by catering to injection-averse patients and is projected to secure a mid-teen percentage of the global obesity drug market, estimated to reach $150 billion by 2030. While Lilly has amassed substantial inventory for its orforglipron, Novo faces manufacturing hurdles for its oral semaglutide due to higher active ingredient requirements, leading to varied analyst peak sales forecasts for both companies.

Analysis

Eli Lilly (LLY) and Novo Nordisk (NVO) are signaling a significant strategic shift in the pharmaceutical pricing model for their upcoming oral GLP-1 obesity drugs. Rather than launching at a premium, both companies are expected to price their pills on par with or slightly below their existing high-priced injections, which list around $1,000 per month. This strategy is primarily dictated by the oral drugs' lower efficacy profiles; Lilly's orforglipron demonstrated a 12.4% weight reduction, and Novo's oral semaglutide 15%, both trailing the up to 21% efficacy of Lilly's Zepbound injection. This has directly impacted forecasts, with peak annual sales estimates for Lilly's orforglipron being revised down from as high as $30 billion to as low as $10 billion. Novo faces substantial execution risk due to manufacturing complexities, as its pill requires approximately 75 times more active ingredient than its injectable counterpart, leading to highly divergent peak sales forecasts ranging from $1 billion to $15 billion. The oral segment is positioned as a niche to capture injection-averse patients, projected to secure a mid-teen percentage share of a global obesity market estimated to reach $150 billion by 2030.

Key Decisions for Investors

• Investors should moderate long-term revenue growth models for Eli Lilly, as the downward revision of its orforglipron peak sales forecast to as low as $10 billion suggests the oral drug will be a smaller contributor than previously expected.
• Closely monitor Novo Nordisk's manufacturing and supply chain updates, as its ability to overcome the significant hurdle of producing 75 times more active ingredient for its pill will be the primary determinant of whether it can meet sales forecasts, which currently show extreme variance between $1 billion and $15 billion.
• Recognize that the oral GLP-1 market is shaping up to be complementary rather than disruptive to injectables, given the efficacy gap, meaning the primary investment thesis for both companies remains centered on their market-leading injection franchises.
• Factor in potential margin pressure for the entire GLP-1 segment, as the decision to price new, more convenient oral formulations at parity with older injections, rather than at a premium, signals a ceiling on pricing power amid growing political and consumer demand for affordability.